Formulation Development Outsourcing Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2024-32
                     Global Formulation 
Development 
Outsourcing Market 
Research and Forecast 
Report 2024-2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
In ternat ional  Market  Analys is  Research and Consul t ing Group is  a leading adv iser  on management  
s t rategy and market  research wor ldwide.  We par tner  wi th c l ients  in  a l l  regions and indust ry  
vert ica ls  to  ident i fy  thei r  h ighest -value oppor tuni t ies,  address thei r  most  cr i t ica l  chal lenges,  and 
t ransform thei r  bus inesses.
IMARC’s in format ion products  inc lude major market ,  sc ient i f ic ,  economic and technological  
developments  for  bus iness leaders  in  pharmaceut ica l ,  indust r ia l ,  and h igh technology 
organizat ions.  Market  forecasts  and indust ry  analys is  for  b iotechnology,  advanced mater ia ls ,  
chemicals ,  food and beverage,  t ravel  and tour ism, nanotechnology and novel  process ing methods 
are at  the top of  the company’s  exper t ise.
IMARC’s ta i lored approach combines unfathomable ins ight  in to the dynamics o f  companies and 
markets wi th c lose cooperat ion at  a l l  levels  of  the c l ient  organizat ion.  This ensures that  our  c l ients 
achieve unmatchable compet i t ive advantage,  bui ld  more pro f ic ient  organizat ions,  and secure 
las t ing resul ts .
A c c o r d i n g  t o  t h e  l a t e s t  r e p o r t  b y  I M A R C  G r o u p ,  t i t l e d  " F o r m u l a t i o n  D e v e l o p m e n t  O u t s o u r c i n g  
M a r k e t :  G l o b a l  I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  G r o w t h ,  O p p o r t u n i t y  a n d  F o r e c a s t  2 0 2 4 -
2 0 3 2 , "  t h e  g l o b a l  f o r m u l a t i o n  d e v e l o p m e n t  o u t s o u r c i n g  m a r k e t  s i z e  r e a c h e d  U S $  2 4 . 2  B i l l i o n  i n  
2 0 2 3 .
F o r m u l a t i o n  d e v e l o p m e n t  i n v o l v e s  c r e a t i n g  a n d  o p t i m i z i n g  a  f o r m u l a t i o n  f o r  a  s p e c i f i c  p r o d u c t  o r  
a p p l i c a t i o n .  T h i s  p r o c e s s  i s  p a r t i c u l a r l y  c o m m o n  i n  p h a r m a c e u t i c a l s ,  c o s m e t i c s ,  f o o d  a n d  
Report b e v e r a g e s  ( F & B ) ,  a n d  a g r o c h e m i c a l  s e c t o r s ,  w h e r e  t h e  p r o d u c t ' s  c o m p o s i t i o n  i s  c r i t i c a l  t o  i t s  
e f f e c t i v e n e s s ,  s t a b i l i t y ,  a n d  o v e r a l l  p e r f o r m a n c e .  F o r m u l a t i o n  d e v e l o p m e n t  o u t s o u r c i n g  r e f e r s  t o  
t h e  p r o c e s s  i n  w h i c h  p h a r m a c e u t i c a l  c o m p a n i e s  d e l e g a t e  t h e  t a s k s  o f  d r u g  f o r m u l a t i o n  a n d  
Highlight and d e v e l o p m e n t  t o  e x t e r n a l  s e r v i c e  p r o v i d e r s .  T h e s e  s e r v i c e  p r o v i d e r s  a r e  u s u a l l y  c o n t r a c t  r e s e a r c h  
o r g a n i z a t i o n s  ( C R O s )  o r  c o n t r a c t  d e v e l o p m e n t  a n d  m a n u f a c t u r i n g  o r g a n i z a t i o n s  ( C D M O s )  w i t h  
s p e c i a l i z e d  e x p e r t i s e  a n d  a d v a n c e d  t e c h n o l o g i c a l  c a p a b i l i t i e s .  D r u g  f o r m u l a t i o n  i n v o l v e s  t h e  
Description d e s i g n  a n d  m a n u f a c t u r e  o f  a  s t a b l e  a n d  e f f e c t i v e  p h a r m a c e u t i c a l  p r o d u c t ,  e n c o m p a s s i n g  a s p e c t s  s u c h  a s  d o s a g e  f o r m ,  c o m p o s i t i o n ,  t a s t e ,  a n d  s h e l f  l i f e .  T h i s  p r o c e s s  c a n  b e  c o m p l e x  a n d  
r e s o u r c e - i n t e n s i v e ,  i n v o l v i n g  n u m e r o u s  s t a g e s  l i k e  p r e - f o r m u l a t i o n ,  p r o t o t y p e  d e v e l o p m e n t ,  
s t a b i l i t y  s t u d i e s ,  s c a l e - u p ,  a n d  p r o c e s s  v a l i d a t i o n .  B y  o u t s o u r c i n g  f o r m u l a t i o n  d e v e l o p m e n t ,  
p h a r m a c e u t i c a l  c o m p a n i e s  c a n  a c c e s s  s p e c i a l i z e d  k n o w l e d g e ,  m i t i g a t e  r i s k s ,  i n c r e a s e  e f f i c i e n c y ,  
r e d u c e  c o s t s ,  a n d  a c c e l e r a t e  t i m e - t o - m a r k e t .
R e q u e s t  f o r  a  P D F  s a m p l e  o f  t h i s  r e p o r t :  
h t t p s : / / w w w . i m a r c g r o u p . c o m / f o r m u l a t i o n - d e v e l o p m e n t - o u t s o u r c i n g - m a r k e t / r e q u e s t s a m p l e
Report Description
G lo b a l  F o r m u la t i o n  D e v e l o p m e n t  O u t s o u r c i n g  M a r k e t  T r e n d s :
T h e  i n c r e a s i n g  p r e v a l e n c e  o f  c h r o n i c  d i s e a s e s ,  s u c h  a s  d i a b e t e s ,  C O P D ,  c a n c e r ,  a s t h m a ,  a r t h r i t i s ,  a n d  A l z h e i m e r ' s  d i s e a s e ,  t h a t  c r e a t e s  
a  p r e s s i n g  n e e d  f o r  n e w  a n d  e f f e c t i v e  d r u g s  t o  a d d r e s s  t h e s e  c o n d i t i o n s  i s  o n e  o f  t h e  m a j o r  f a c t o r s  d r i v i n g  t h e  m a r k e t  g r o w t h .  
A d d i t i o n a l l y ,  t h e  g r o w i n g  d e m a n d  f o r  h i g h l y  s p e c i a l i z e d  k n o w l e d g e  a n d  s k i l l s  i n  v a r i o u s  s c i e n t i f i c  d i s c i p l i n e s ,  s u c h  a s  c h e m i s t r y ,  
p h a r m a c y ,  f o o d  s c i e n c e ,  o r  c o s m e t i c  t e c h n o l o g y ,  a n d  t h e  e x p e r t i s e  o f  s p e c i a l i z e d  c o n t r a c t  d e v e l o p m e n t  o r g a n i z a t i o n s  ( C D O s )  t h a t  h a v e  
d e d i c a t e d  t e a m s  w i t h  e x t e n s i v e  e x p e r i e n c e  i n  f o r m u l a t i n g  s p e c i f i c  t y p e s  o f  p r o d u c t s  a r e  a c t i n g  a s  o t h e r  g r o w t h - i n d u c i n g  f a c t o r s .  
M o r e o v e r ,  t h e  r i s i n g  p o p u l a r i t y  o f  o u t s o u r c i n g  t h a t  p r o v i d e s  c o m p a n i e s  w i t h  t h e  f l e x i b i l i t y  t o  a d a p t  t o  c h a n g i n g  m a r k e t  d e m a n d s  a n d  t h e  
n e e d  f o r  t h e  d e v e l o p m e n t  o f  n e w  p r o d u c t s  o r  a d j u s t m e n t s  i n  t h e  e x i s t i n g  f o r m u l a t i o n s ,  a l l o w i n g  f o r  q u i c k  a c c e s s  t o  a d d i t i o n a l  r e s o u r c e s  
w i t h o u t  l o n g - t e r m  c o m m i t m e n t s ,  i s  c r e a t i n g  a  p o s i t i v e  o u t l o o k  f o r  t h e  m a r k e t .  A d d i t i o n a l l y ,  t h e  i n c r e a s i n g  u t i l i z a t i o n  o f  o u t s o u r c i n g  t o  
C R O s  w i t h  e s t a b l i s h e d  p r o t o c o l s  a n d  w o r k f l o w s ,  l e a d i n g  t o  f a s t e r  a n d  m o r e  c o s t - e f f i c i e n t  d e v e l o p m e n t ,  h e l p i n g  c o m p a n i e s  s a v e  t i m e  a n d  
r e s o u r c e s  i n  b r i n g i n g  n e w  d r u g s  t o  m a r k e t ,  i s  f a v o r i n g  t h e  m a r k e t  g r o w t h .  B e s i d e s  t h i s ,  t h e  i n c r e a s i n g  n e e d  t o  i n n o v a t e  a n d  d e v e l o p  n o v e l  
m e d i c i n e s  t h e  r e p l a c e  t h e  l o s t  r e v e n u e  c a u s e d  d u e  t o  p a t e n t  e x p i r a t i o n  i s  p r o v i d i n g  r e m u n e r a t i v e  g r o w t h  o p p o r t u n i t i e s .
L o o k in g  f o r w a r d ,  t h e  m a r k e t  v a lu e  i s  p r o j e c t e d  t o  r e a c h  U S $  4 0 .4  B i l l i o n  b y  2 0 3 2 ,  e x p a n d in g  a t  a  C A G R  o f  5 .6 %  d u r in g  
2 0 2 4 - 2 0 3 2 .
V ie w  R e p o r t  T O C ,  F i g u r e s  a n d  T a b l e s :  h t t p s : / / w w w . i m a r c g r o u p . c o m / f o r m u la t i o n - d e v e lo p m e n t - o u t s o u r c i n g - m a r k e t
Breakup by Service:
• Pre- formulat ion Services
o Discovery and Precl in ica l  Services
o Analyt ica l  Services
• Formulat ion Opt imizat ion
o  Phase I
o Phase I I
o Phase I I I
Report o Phase IV
Segmentation
Breakup by Dosage Form:
• In jectable
• Oral
• Topica l
• Others
Breakup by Application:
• Oncology
• Genetic  Disorders
• Neurology
• Infect ious Diseases
• Respi ratory
• Cardiovascular
• Others
Report Breakup by End User:
• Pharmaceutica l  and Biopharmaceut ica l  Companies
Segmentation • Government and Academic Inst i tutes
Breakup by Region:
• North America
• Asia-Pac ifi c
• Europe
• Lat in America
• Middle East and Afr ica
• Aizant Drug Research Solut ions Pr ivate Limited
• Catalent Inc.
• Char les River  Laborator ies
• Dr.  Reddy’s Laborator ies Ltd.
Competitive • Emergent  BioSolut ions Inc.
• Intertek Group plc
Landscape 
• I r isys LLC (Recro Pharma)
with Key • Laboratory Corporat ion of  America Holdings
• Lonza Group AG
Players
• Piramal Pharma Solut ions
• Quot ient Sciences
• Syngene Internat ional  L imited (Biocon L imited)
• Thermo Fisher  Scient ifi c Inc.
How has the global formulation development 
outsourcing market performed so far and how will it 
perform in the coming years?
What has been the impact of COVID-19 on the global 
formulation development outsourcing market?
Key What are the key regional markets?
Questions 
Answered in What is the breakup of the market based on the service?
the Report
What is the breakup of the market based on the dosage 
form?
What is the breakup of the market based on the 
application?
What is the breakup of the market based on the end 
user?
What are the various stages in the value chain of the 
industry?
What are the key driving factors and challenges in the 
industry?
Key 
What is the structure of the global formulation 
Questions development outsourcing market and who are the key players?
Answered in 
What is the degree of competition in the industry?
the Report
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
        2 . 4 . 1     B o t t o m - U p  A p p r o a c h
Table of         2 . 4 . 2     T o p - D o w n  A p p r o a c h    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4     I n t r o d u c t i o n
    4 . 1     O v e r v i e w
Contents     4 . 2     K e y  I n d u s t r y  T r e n d s5     G l o b a l  F o r m u l a t i o n  D e v e l o p m e n t  O u t s o u r c i n g  M a r k e t
    5 . 1     M a r k e t  O v e r v i e w
    5 . 2     M a r k e t  P e r f o r m a n c e
    5 . 3     I m p a c t  o f  C O V I D - 1 9
    5 . 4     M a r k e t  F o r e c a s t
6      M a r k e t  B r e a k u p  b y  S e r v i c e
    6 . 1     P r e - f o r m u l a t i o n  S e r v i c e s
        6 . 1 . 1  M a r k e t  T r e n d s
        6 . 1 . 2  K e y  S e g m e n t s
           6 . 1 . 2 . 1  D i s c o v e r y  a n d  P r e c l i n i c a l  S e r v i c e s
           6 . 1 . 2 . 2  A n a l y t i c a l  S e r v i c e s
        6 . 1 . 3  M a r k e t  F o r e c a s t
    6 . 2     F o r m u l a t i o n  O p t i m i z a t i o n
        6 . 2 . 1  M a r k e t  T r e n d s
        6 . 2 . 2  K e y  S e g m e n t s
           6 . 2 . 2 . 1  P h a s e  I
       
           6 . 2 . 2 . 2  P h a s e  I I
           6 . 2 . 2 . 3  P h a s e  I I I
           6 . 2 . 2 . 4  P h a s e  I V
        6 . 2 . 3  M a r k e t  F o r e c a s t
7    M a r k e t  B r e a k u p  b y  D o s a g e  F o r m
    7 . 1     I n j e c t a b l e
        7 . 1 . 1  M a r k e t  T r e n d s
        7 . 1 . 2  M a r k e t  F o r e c a s t
    7 . 2     O r a l
        7 . 2 . 1  M a r k e t  T r e n d s
        7 . 2 . 2  M a r k e t  F o r e c a s t
Table of     7 . 3     T o p i c a l        7 . 3 . 1  M a r k e t  T r e n d s
        7 . 3 . 2  M a r k e t  F o r e c a s t
    7 . 4     O t h e r s
Contents         7 . 4 . 1  M a r k e t  T r e n d s        7 . 4 . 2  M a r k e t  F o r e c a s t
8    M a r k e t  B r e a k u p  b y  A p p l i c a t i o n
    8 . 1     O n c o l o g y
        8 . 1 . 1  M a r k e t  T r e n d s
        8 . 1 . 2  M a r k e t  F o r e c a s t
    8 . 2     G e n e t i c  D i s o r d e r s
        8 . 2 . 1  M a r k e t  T r e n d s
        8 . 2 . 2  M a r k e t  F o r e c a s t
    8 . 3     N e u r o l o g y
        8 . 3 . 1  M a r k e t  T r e n d s
        8 . 3 . 2  M a r k e t  F o r e c a s t
    8 . 4     I n f e c t i o u s  D i s e a s e s
        8 . 4 . 1  M a r k e t  T r e n d s
        8 . 4 . 2  M a r k e t  F o r e c a s t
F o r  m o r e  i n f o r m a t i o n ,  v i s i t :  
h t t p s : / / w w w. im a rcg ro u p . co m / f o rm u la t i o n - de v e lo p m e n t - o u t s o u rc i
n g - m a r ke t / t o c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: